Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions

Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaqu...

Full description

Bibliographic Details
Main Authors: Juan Carlos Frías, Michael Joseph Lipinski, María Teresa Albelda, Borja Ibáñez, Conxa Soriano, Enrique García-España, Luis Jesús Jiménez-Borreguero, Juan José Badimon
Format: Article
Language:English
Published: SAGE Publishing 2008-01-01
Series:Clinical Medicine Insights: Cardiology
Online Access:https://doi.org/10.4137/CMC.S642
id doaj-05f880d4ce9f4780a6d57a556c42008e
record_format Article
spelling doaj-05f880d4ce9f4780a6d57a556c42008e2020-11-25T03:28:14ZengSAGE PublishingClinical Medicine Insights: Cardiology1179-54682008-01-01210.4137/CMC.S642Nanoparticles as Contrast Agents for MRI of Atherosclerotic LesionsJuan Carlos Frías0Michael Joseph Lipinski1María Teresa Albelda2Borja Ibáñez3Conxa Soriano4Enrique García-España5Luis Jesús Jiménez-Borreguero6Juan José Badimon7Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA, U.S.A.Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, U.S.A.Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.Instituto de Ciencia Molecular, University of Valencia, Valencia, Spain.Departamento de Cardiología, Hospital Universitario de La Princesa, Madrid, Spain.The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, U.S.A.Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaque rupture. By increasing molecular flexibility or adding a means of specifically targeting ligands via antibody or peptide, nanoparticles can enhance certain regions of the atherosclerotic plaque. The development of single contrast agents detectable with multiple imaging modalities may further improve our ability to detect and characterize atherosclerosis in clinical and preclinical applications. These exciting developments may help in the realization of MRI as a powerful tool in the prevention of cardiovascular morbidity and mortality.https://doi.org/10.4137/CMC.S642
collection DOAJ
language English
format Article
sources DOAJ
author Juan Carlos Frías
Michael Joseph Lipinski
María Teresa Albelda
Borja Ibáñez
Conxa Soriano
Enrique García-España
Luis Jesús Jiménez-Borreguero
Juan José Badimon
spellingShingle Juan Carlos Frías
Michael Joseph Lipinski
María Teresa Albelda
Borja Ibáñez
Conxa Soriano
Enrique García-España
Luis Jesús Jiménez-Borreguero
Juan José Badimon
Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
Clinical Medicine Insights: Cardiology
author_facet Juan Carlos Frías
Michael Joseph Lipinski
María Teresa Albelda
Borja Ibáñez
Conxa Soriano
Enrique García-España
Luis Jesús Jiménez-Borreguero
Juan José Badimon
author_sort Juan Carlos Frías
title Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
title_short Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
title_full Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
title_fullStr Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
title_full_unstemmed Nanoparticles as Contrast Agents for MRI of Atherosclerotic Lesions
title_sort nanoparticles as contrast agents for mri of atherosclerotic lesions
publisher SAGE Publishing
series Clinical Medicine Insights: Cardiology
issn 1179-5468
publishDate 2008-01-01
description Nanoparticle contrast agents for MRI may aid in identifying atherosclerotic lesions that give rise to ischemic events by means of penetration and retention in the plaque. These imaging agents may provide valuable information regarding plaque characteristics which can help determine the risk of plaque rupture. By increasing molecular flexibility or adding a means of specifically targeting ligands via antibody or peptide, nanoparticles can enhance certain regions of the atherosclerotic plaque. The development of single contrast agents detectable with multiple imaging modalities may further improve our ability to detect and characterize atherosclerosis in clinical and preclinical applications. These exciting developments may help in the realization of MRI as a powerful tool in the prevention of cardiovascular morbidity and mortality.
url https://doi.org/10.4137/CMC.S642
work_keys_str_mv AT juancarlosfrias nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT michaeljosephlipinski nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT mariateresaalbelda nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT borjaibanez nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT conxasoriano nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT enriquegarciaespana nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT luisjesusjimenezborreguero nanoparticlesascontrastagentsformriofatheroscleroticlesions
AT juanjosebadimon nanoparticlesascontrastagentsformriofatheroscleroticlesions
_version_ 1724585514640605184